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PEndothelial Function in Women
Prognostic Role of Flow-Mediated Dilation
and Cardiac Risk Factors in Post-Menopausal Women
Rosario Rossi, MD,* Annachiara Nuzzo, MD,* Giorgia Origliani, PHD,†
Maria Grazia Modena MD, FACC*
Modena, Italy
Objectives The aim of this study was to examine the association between brachial artery flow-mediated dilation (FMD) and
cardiovascular events in a cohort of initially asymptomatic post-menopausal women, with adjustment for the
presence of the major cardiovascular risk factors.
Background Conventional major cardiovascular risk factors (cigarette smoking, hypercholesterolemia, hypertension, and dia-
betes) fail to explain nearly 50% of cardiovascular events. Defining the magnitude of future risk for the develop-
ment of clinical events is a major focus of effective primary prevention. Evaluation of endothelial function, utiliz-
ing the noninvasive measurement of the brachial artery FMD, may serve as a screening tool to individualize
high-risk patients.
Methods We conducted a prospective study on 2,264 post-menopausal women, age 54  6 years. The length of the
follow-up was 45  13 months (range 6 to 65 months).
Results During observation, 90 major events were recorded. Risk-adjusted relative risk values resulted 1.0, 1.33 (95%
confidence interval [CI] 1.09 to 4.09), and 4.42 (95% CI 2.97 to 8.01) for women in the higher, intermediate,
and lower tertile of FMD, respectively (p  0.0001 for trend). The event rate for women in the lower tertile (FMD
4.5%) was greater than the combined event rate noted in the other 2 tertiles (women in the lower tertile ac-
counted for 51 events [56.6% of total events]). When added to age and other conventional cardiovascular risk
factors (smoking habits, presence of hypercholesterolemia, history of diabetes, hypertension), FMD contributed
significantly to the model predicting cardiovascular events (likelihood ratio chi-square change: 10.22; p 
0.0001).
Conclusions In post-menopausal women, the knowledge of FMD provided incremental prognostic information regarding the
risk of developing cardiovascular events. (J Am Coll Cardiol 2008;51:997–1002) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.044C
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eardiovascular diseases (CVDs) are the primary cause of
eath in all industrialized countries, and will most likely
emain the leading cause of death well into the 21st century
1–3). Prospective epidemiologic studies have established
he association between major risk factors (age, cigarette
moking, hypercholesterolemia, diabetes, and hypertension)
nd the development of cardiovascular (CV) events (4–7).
owever, it has been estimated that these risk factors fail to
xplain up to 50% of the CVD morbidity and mortality
2,4,8). According to Framingham data, nearly 50% of all
rom the *Institute of Cardiology, Policlinico Hospital, University of Modena and
eggio Emilia, Modena, Italy; and †Centro “Bene Essere Donna,” Azienda Poli-
linico di Modena, Modena, Italy. Partly supported by grant from the MIUR
MInistero dell’Università e della Ricerca), Rome, Italy. Preliminary results of this
tudy were presented at the 55th Annual Scientific Sessions of the American College
f Cardiology; Atlanta, Georgia, March 11 to 15, 2006.C
Manuscript received September 12, 2006; revised manuscript received October 30,
007, accepted November 8, 2007.V events occur in individuals with no previous history of
ymptomatic heart diseases (9–11). Thus, defining the
agnitude of future risk for the development of clinical
VD is a major focus of effective primary prevention.
One proposed screening strategy for searching the patient
usceptible to an acute CV event (defined as “vulnerable
atient” by Naghavi et al. [12]) uses the noninvasive measure-
ent of the flow-mediated dilation (FMD) in the brachial
rtery, utilizing a high-resolution ultrasound method (“endo-
helial dysfunction, as measured by impaired FMD in the
rachial artery, can aid in the detection of pan-arterial vulner-
bility and may serve as a screening tool” [12]).
The impairment of endothelial function is the primary
tiology implicated in the origin and development of ath-
rosclerotic CVD (13). Since 1992, the noninvasive mea-
urement of brachial artery FMD has been used to evaluate
ndothelial function (14), which is considered a marker of
VD risk (15–18).
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FMD and Prognosis in Women March 11, 2008:997–1002The aim of this study was to
examine the association between
FMD and CV events in a cohort
of initially asymptomatic post-
menopausal women, with adjust-
ment for the presence of the
major CV risk factors.
Methods
Patient selection. We conducted
a prospective study on 2,264
post-menopausal women, age
55  6 years (range 47 to 60
years), all self-referred to the
“Bene Essere Donna” center, an
nstitution dedicated to the study, prevention, and treatment
f menopause-related disorders. This service, located in a
hird-level university hospital, is open to all women provid-
ng they are in their post-menopausal period (post-
enopausal status was defined as the absence of menstrua-
ion for at least 6 months and/or by a follicle-stimulating
ormone blood level 40 IU/l and 17 beta-estradiol levels
120 pmol/l) and are60 years of age. These women, who
re initially drawn to the center through local media
dvertising, have free access and can make queries or obtain
dvice about particular symptoms they are having by sched-
ling an appointment beforehand. Physical examination
ariables measured at baseline included body weight, height,
aist circumference, and systolic and diastolic blood pres-
ure. Patient history, 12-lead electrocardiogram, and echo-
ardiogram were used to exclude past or present heart
isease. At baseline each participant had fasting blood tests
or levels of glucose and total cholesterol. Participants
rovided questionnaire data concerning life-style potential
isk factors for CVD (cigarette smoking, hypercholesterol-
mia, diabetes, and hypertension). Hypercholesterolemia
as defined as a total cholesterol level of200 mg/dl or the
se of cholesterol-lowering medications. Individuals were
onsidered to be diabetic patients in the presence of a fasting
lood glucose 126 mg/dl or if they reported using oral
ypoglycemic agents and/or insulin; and hypertensive in
resence of high blood pressure values (140/90 mm Hg)
r if they reported a history of high blood pressure and use
f antihypertensive medications.
Patients with a past medical history of chest pain,
iagnostic coronary angiography, coronary revasculariza-
ion, myocardial infarction, stroke or transient ischemic
ttack (TIA), and previous or current use of hormone
eplacement therapy were excluded from the study.
The length of the follow-up was 45  13 months (range
to 65 months). All participants gave their written in-
ormed consent to participate in this study, which had been
pproved by the science and ethics committee of our
Abbreviations
and Acronyms
CV  cardiovascular
CVD  cardiovascular
disease
FMD  flow-mediated
dilation
NO  nitric oxide
TIA  transient ischemic
attack
t-PA  tissue-type
plasminogen activator
u-PA  urokinase-type
plasminogen activatornstitution. eetermination of CV events. Events in this study were
efined as the occurrence of 1 of the following: 1) cardiac-
elated death; 2) myocardial infarction; and 3) revascular-
zation procedure (catheter-based or surgically), TIA, and
troke. Only confirmed events were included in this analysis,
nd only 1 event per person was counted in the order of its
ccurrence. Efforts were made to determine the cause of
eath: review of hospital records and death certificates as
ell as conversations with family members. Deaths unre-
ated to heart disease were excluded from this analysis.
eported events were verified in all cases with medical
ecords and/or death certificates.
valuation of FMD. Endothelial function was evaluated
hrough the measure of the FMD performed on the brachial
rtery. Flow-mediated dilation was measured unaware of
he clinical data. The technique for assessing brachial artery
MD has been described in detail elsewhere (14,19–22).
riefly, FMD was assessed in the subject’s right arm in the
ecumbent position after a 15-min equilibration period in a
emperature-controlled room (22°C to 25°C) by a Acuson
28 XP/10 mainframe (Acuson, Mountain View, Califor-
ia) with a 7.5-MHz linear array transducer. The brachial
rtery was longitudinally imaged 5 cm proximal to the
ntecubital crease, where the clearest image was obtained,
nd the diameter at end diastole was measured (the mean of
measurements was used in the analysis). A pressure cuff,
laced on the forearm (distal to the target artery), was
nflated until no blood flow was detected through the
rachial artery with the Doppler probe. After 5 min, the cuff
as released, and this was followed by an increase in blood
ow. This phenomenon increased shear stress, which served
s the stimulus to induce dilation. After cuff release, the
iameter of the brachial artery was measured at 45, 60, 90,
80, and 300 s. The maximum diameter in any of these
easurements was used in the calculation of FMD accord-
ng to the following formula: (maximum diameter during
eactive hyperemia  diameter at baseline)/diameter at
aseline  100.
In our laboratory, the methodology has an interobserver
ariability in diameter measurements of 0.45  0.25%,
ielding a coefficient of variation of 1.34% and a coefficient
f repeatability of 0.8%. The day-to-day variability was calcu-
ated on 50 consecutive women of our center, and resulted in
.64  0.35% in brachial artery diameter measurements.
tatistical analysis. Descriptive statistics were used to
ummarize the baseline characteristics, CV risk factors
nformation, and FMD. Women were categorized for the
rimary analysis on the basis of the severity of endothelial
ysfunction, according to the tertile cut points of FMD.
aseline values of all studied characteristics were compared
cross tertiles using a nonparametric test for trend across the
rdered groups (Jonckheere-Terpstra test).
Student t test or chi-square test, when appropriate, was
sed in the comparison of women who sustained any CV
vents versus women without events.
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March 11, 2008:997–1002 FMD and Prognosis in WomenThe associations between risk factors, FMD, and CV
vents were examined by use of the Pearson chi-square test,
ultivariate logistic regression, and Cox proportional haz-
rds regression. Hierarchical Cox proportional hazards re-
ression was used to compare 2 nested models, including: 1)
ge and other major risk factors (smoking habits, the
resence of diabetes, hypertension, and hypercholesterol-
mia), and 2) age, major risk factors, and FMD. The
ikelihood ratio chi-square statistics were obtained to deter-
ine whether the addition of FMD contributed signifi-
antly to the models predicting CV events. The initial
odel included only age and other conventional risk factors.
low-mediated dilation was subsequently added to the
odel. We computed crude and multiple-adjusted hazard
atios (and 95% confidence intervals) as a measure of the
elative risks of CV events for decreasing percent of FMD,
ith the highest tertile as the referent. Differences between
he different strata of women were evaluated with the
hi-square test (linear-by-linear association). The signifi-
ance level was set at a value of p  0.05.
esults
he baseline characteristics of our population are illustrated
n Table 1; the 2,264 women were divided in 3 groups
ccording to the tertiles of FMD.
During the follow-up period, 91 events were reported.
fter 1 death unrelated to heart disease had been excluded,
0 confirmed CV events (47 TIAs, 21 ischemic strokes, 9
cute myocardial infarctions, 10 hospitalizations for coro-
ary revascularization, 3 cardiac-related deaths) were used
n the analysis.
Compared with those without events, women who sus-
ained any event were older (mean age 57  6 years vs.
2  7 years, p  0.001) and had a higher prevalence of
moking (31.1% [28 of 90] vs. 17.6% [384 of 2,174], p 
.001), diabetes (13.3% [12 of 90] vs. 3.49% [76 of 2,174],
 0.0001), hypertension (45.5% [41 of 90] vs. 20.1% [437
f 2,174], p  0.0001), and hypercholesterolemia (26.6%
24 of 90] vs. 18.3% [398 of 2,174], p  0.01).
Baseline Characteristics of the Study ParticipanDivided in Groups According to the Tertiles of F
Table 1 Baseline Characteristics of the StuDivided in Groups According to the
3° (Higher) Tertile
n 754
Levels of FMD, % 8.1
BAD, cm 3.9 0.6
Age, yrs 53 7
Caucasian, % 100 (n  754)
Time from menopause, months 33 13
Cigarette use, % 12.4 (94 of 754)
Hypercholesterolemia, % 11.6 (88 of 754)
Diabetes, % 1.8 (14 of 754)
Hypertension, % 14.9 (113 of 754)
Data are expressed as mean 1 standard deviation or as a percentage
dilation (FMD).
BAD  brachial artery diameter.The univariate and multivariate association between the
isk factors, FMD, and CV events is shown in Table 2.
ontrolling for age and other risk factors (smoking habits,
resence of hypercholesterolemia, history of diabetes, hy-
ertension), FMD was significantly associated with the
ncidence of CV events.
In the hierarchical Cox proportional hazards regression
nalysis, FMD resulted as a significant contributor to the
odel predicting CV events (likelihood ratio chi-square
hange  10.22, which represents a strong significant
hange in goodness-of-fit measure; p  0.0001).
The event rate and the relative risk for CV events at
ncreased tertile of FMD were graded as shown in Table 3.
he event rate among patients in the lowest tertile of FMD
as greater than the combined event rate observed in the
ther 2 tertiles (women in the lower tertile accounted, in
act, for 51 events [56.6% of total events]).
iscussion
therosclerosis, the leading cause of morbidity and mortal-
ty in Western countries, is a systemic disease that infiltrates
he arterial wall before it cause significant obstruction of
lood flow and ischemic symptoms. In the last decade, the
creening of asymptomatic individuals to detect latent dis-
ase has become a topic of great interest. The rationale for
nvestigating the presence of pre-clinical atherosclerosis
esides in the fact that more than one-half of all CV events
ake place in previously asymptomatic patients (23,24).
hus, in prevention, the emphasis has recently been focused
n the identification of high-risk individuals with a high-
isk of developing CV events (25,26). In our opinion, 2
ritical issues of this topic deserved an answer. First of all,
oes the knowledge of the FMD supply an added value to
ur ability to predict the risk of developing CV events, and,
f yes, to what degree can FMD predict events in our specific
opulation? To attempt to answer these questions, we
valuated a large population of initially asymptomatic post-
enopausal women with risk factors for atherosclerosis.
ur results show that FMD adds prognostic information
rticipants
les of FMD
ntermediate) Tertile 1° (Lower) Tertile p Value*
755 755 —
4.6–8.0 4.5 —
4.0 0.5 3.8 0.7 NS
55 7 56 6 0.001
00 (n  755) 100 (n  755) NS
52 15 62 15 0.001
6.0 (121 of 755) 26.0 (197 of 755) 0.0001
9.3 (146 of 755) 24.9 (188 of 755) 0.0001
3.0 (23 of 755) 6.7 (51 of 755) 0.0001
7.7 (134 of 755) 30.6 (231 of 755) 0.0001
bability values for ordered differences across tertiles of flow-mediatedtsMD
dy Pa
Terti
2° (I
1
1
1
1
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FMD and Prognosis in Women March 11, 2008:997–1002bove and beyond knowledge of traditional risk factors. In
act, the ability to classify and predict an event improved
nce FMD was added to risk factors.
It is well known that FMD induced by reactive hyper-
mia is endothelium dependent (27,28); in other words, it
epends on the ability of the endothelium to produce
ilator-endowed substances, mainly nitric oxide (NO). It is
ell demonstrated that post-menopausal status is associated
ith a significantly reduced arterial NO activity (29). It is
easonable to conclude that our patients with a lower level of
MD had worse endothelial function, and some important
athological effects are influenced by endothelial dysfunc-
ion. Disruption of atherosclerotic plaques is the most
requent cause of acute thrombo-embolic events, and these
vents include death, acute coronary syndromes, and stroke
30). Endothelial dysfunction often is found in ruptured
laques, as well as in plaques that show superficial erosion
31–34). Further, the endothelium has an important anti-
hrombotic role. Nitric oxide and prostacyclin act synergis-
ically to prevent platelet adhesion and aggregation (35,36).
he regulation of fibrinolysis is another important func-
nivariate and Multivariate Association Betweenisk Factors, F D, and Cardiovascular Events iur Population of 2,264 Women
Table 2
Univariate and Multivariate Association Between
Risk Factors, FMD, and Cardiovascular Events in
Our Population of 2,264 Women
Univariate
Multivariate
(6-Predictor Model)*
RR 95% CI RR 95% CI
Age (yrs) 1.42† 1.16–2.44 1.23† 1.04–1.97
Smoking habits (yes/no) 1.77‡ 1.20–2.66 1.22§ 1.03–2.19
Hypercholesterolemia (yes/no) 1.44§ 1.11–1.95 1.07 1.02–1.77
Diabetes (yes/no) 3.80† 2.06–6.00 2.96† 1.68–4.09
Hypertension (yes/no) 2.25‡ 1.40–3.10 1.76‡ 1.14–2.34
FMD (%) 1.31† 1.12–2.55 1.12† 1.04–2.00
The 6-predictor Cox proportional hazards regression model included simultaneously all variables
isted in the table (age, smoking habits, hypercholesterolemia, diabetes, hypertension); †p 
.0001; ‡p  0.001; §p  0.01; p  0.05.
CI  confidence interval; FMD  flow-mediated dilation; RR  relative risk.
Cardiovascular Event Rates and Association BeFMD Tertiles and Cardiova cular Events in Our P
Table 3 Cardiovascular Event Rates and AsFMD Tertiles and Cardiovascular Ev
3° (Higher)
Tertile
(FMD >8.1%)
TIA, % 0.26 (2 of 754)
Ischemic stroke, % 0.39 (3 of 754)
Nonfatal myocardial infarction, % 0.26 (2 of 754)
Hospitalization for coronary
revascularization, %
0.13 (1 of 754)
Cardiac-related death, % 0
Cardiovascular events (total), % 1.06 (8 of 754)
Relative risk (crude) 1.0
95% CI Referent
Relative risk (adjusted for age and
other conventional risk factors)
1.0
95% CI Referent*p is the overall significance between groups, calculated by chi-square test, l
TIA  transient ischemic attack; other abbreviations as in Table 2.ion of the normal endothelium. The 2 principal deter-
inants of fibrinolysis are: 1) tissue-type plasminogen
ctivator (t-PA) and urokinase-type plasminogen activa-
or (u-PA), which promote fibrinolysis; and 2) plasmin-
gen activator inhibitor type 1, which inhibits t-PA and
-PA and enhances formation of thrombi. In normal
lood vessels, a basal level of t-PA is secreted, which
revents thrombus formation in the absence of vascular
njury (37). In the presence of endothelial dysfunction,
nhanced platelet deposition, thrombus formation, and
nhibition of dilation may also explain the high incidence
f transient ischemic episodes in the cerebral vascular
erritory (21).
isk assessment strategies. Despite extensive studies and
evelopment of several risk prediction models, traditional
isk factors fail to predict development of CV events in a
arge group of cases (3,5,6,38). The extensive use of the
ost famous risk prediction model was proposed by the
ational Cholesterol Education Program III guidelines, in
hich the approach offered by the Framingham risk score to
ormulate a 10-year risk of CV events was embraced (39).
oday it is clear that the Framingham risk score as well as
everal other risk factor assessment models (40,41) have
een shown to predict long-term outcome in a large
opulation, but may not be able to predict short-term risk
or individual persons, and cannot provide clear indications
or cardiologists to identify and treat, to prevent near future
ictims of acute CV events (42). Hence, there is a need to
mprove risk prediction. In our study, all of the established
isk factors were predictive of CV events in the univariate
nd multivariate analysis, but when FMD was added to the
odel, it was a significant predictor of outcome and added
ndependently to the risk prediction.
Atherosclerosis is a diffuse and systemic disease involving
ascular, metabolic, and immune systems, with several local
anifestations. Therefore, it is essential to precisely assess
he total vulnerability burden of the vascular system, rather
nation
tion Between
in Our Population
° (Intermediate)
Tertile
From 4.6% to 8.0%)
1° (Lower)
Tertile
(FMD <4.5%) p Value*
1.72 (13 of 755) 4.23 (32 of 755) 0.0001
1.05 (8 of 755) 1.32 (10 of 755) 0.01
3.97 (3 of 755) 5.29 (4 of 755) 0.05
0.92 (7 of 755) 0.26 (2 of 755) NS
0 0.39 (3 of 755) NS
4.10 (31 of 755) 6.75 (51 of 755) 0.0001
3.87 6.36 0.0001
2.05–8.55 4.26–11.50 —
1.33 4.42 0.0001
1.09–4.09 2.97–8.01 —tweeopul
socia
ents
2
(FMDinear-by-linear association.
t
t
i
w
e
f
f
n
o
a
t
S
i
a
e
t
y
a
(
c
q
q
n
r
t
a
p
h
o
F
i
t
n
i
s
l
i
i
t
n
A
b
w
C
I
f
p
f
R
t
M
R
1
1
1
1
1
1
1
1
1
1
2
2
2
1001JACC Vol. 51, No. 10, 2008 Rossi et al.
March 11, 2008:997–1002 FMD and Prognosis in Womenhan search for a single, unstable plaque (42). According to
his approach, the study of the endothelial function may be
mportant, because an impaired endothelial dilator function
as demonstrated during acute and chronic CVD (43–45),
ndothelial vasomotor function was defined as “the risk
actor of the risk factors” because patients with CV risk
actor have endothelial dysfunction (43), and, finally, vul-
erable plaques in several arterial districts have multiple sites
f active inflammation and oxidative stress, and this is
ssociated with an impaired systemic endothelial dysfunc-
ion (46,47).
tudy limitations. Our study has some limitations, in that
t is an observational study, which shows an interesting
ssociation between FMD and risk of developing CV
vents.
An important limit of our study is that the admittance
o our center is completely free for all women age 60
ears. For this reason we constructed a relatively young
ge group. We built our activity to make every woman
with the only limitation of age) free to come to our
enter when she needs to have any problem solved, to ask
uestions, to receive suggestions, and so on. As a conse-
uence, the incidence of CV risk factors and CV events
oted in our sample of patients could be different as
egards what would be registered in the general popula-
ion of post-menopausal women.
Another limit is that in the present study we could not
nalyze the influence of some major risk factors, such as the
resence of paroxysmal atrial fibrillation, the levels of
igh-density lipoprotein cholesterol, and the concentration
f C-reactive protein. In addition, the predictive value of
MD still needs to be assessed in a model including these
mportant markers of CVD risk.
Although the present data is encouraging, it is oppor-
une to specify that the routine clinical use of the
oninvasive evaluation of endothelial function on an
ndividual basis may be premature, because the test is not
till completely standardized and is costly and rather
abor intensive. Moreover, the value of the present study
s to provide biological insight rather than practical
mplications.
However, the study presents several strengths including
he prospective design, the relatively large and homoge-
eous sample, and the strict follow-up of the participants.
ll of these factors encourage us to hypothesize a causal link
etween FMD and incident CV events in post-menopausal
omen.
onclusions
n our study on the incidence of CV events, FMD was
ound to be an independent risk determinant and adds
rognostic information above and beyond traditional risk
actors.eprint requests and correspondence: Dr. Rosario Rossi, Insti-
ute of Cardiology, Policlinico Hospital, Via del Pozzo, 71-41100
odena, Italy. E-mail: rossi.rosario@unimore.it.
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